Diagnostic Accuracy of MRI in Evaluating Response After Neoadjuvant Systemic Therapy in Operable Breast Cancer

被引:6
|
作者
Khazindar, Abdullah R. [1 ]
Hashem, Dalia Abdulmonem L. [2 ]
Abusanad, Atlal [3 ]
Bakhsh, Salwa, I [4 ]
Bin Mahfouz, Alya [5 ]
El-Diasty, Mohamed T. [5 ]
机构
[1] Univ Jeddah, Dept Radiol, Jeddah, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Diagnost Radiol, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Dept Med, Jeddah, Saudi Arabia
[4] King Abdulaziz Univ, Dept Pathol, Jeddah, Saudi Arabia
[5] King Abdulaziz Univ Hosp, Dept Radiol, Jeddah, Saudi Arabia
关键词
breast cancer; magnetic resonance imaging; complete pathological response; accuracy; radiological complete response; neoadjuvant chemotherapy; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY;
D O I
10.7759/cureus.15516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Neoadjuvant chemotherapy (NAC) is an important step in the treatment of various types of breast cancer by downsizing the tumor to make it operable. Determining disease extent after NAC is essential for accurate surgical planning. MRI has been the gold standard for detecting tumors that are usually difficult to detect on ultrasound or mammography. However, the use of MRI after NAC is controversial. Therefore, we aimed to evaluate the diagnostic accuracy of post-NAC MRI in the detection of residual disease preoperatively and to investigate the factors associated with pathological complete response (pCR). Methodology This retrospective review study was approved by the institutional review board with waiving of the informed consent. A total of 90 charts between January 2016 and January 2019 were reviewed. Baseline lesion size was measured as the maximal diameter in a single dimension by pretreatment MRI. To assess the diagnostic accuracy of MRI in detecting residual disease, we used two different definitions of pCR in the breast. The first is the resolution of both invasive disease and ductal carcinoma in situ. The second is the resolution of the invasive disease only. As a secondary objective of the study, we assessed the association between different patients' characteristics and both MRI and pathologic response using univariate and multivariate analysis. Results A total of 52 women (mean age: 47.4 years; range: 28-74) with 56 breast masses were eligible for the study. Complete MRI response was noted in 22 ( 39%) masses. pCR was achieved in 14 (25%) and 25 (44.6%) masses using the first and second pCR definitions, respectively. The negative predictive value (NPV) and overall accuracy of MRI for detecting residual disease were 50% and 75%, respectively, using the first pCR definition. With the second pCR definition, NPV and accuracy were 77.3% and 76.8%, respectively. Positive axillary lymph nodes were the only significant factor associated with incomplete MRI and pathological responses. Conclusions MRI NPV for residual disease was higher with the second pCR definition; however, overall accuracy was not different. MRI accuracy in detecting residual disease after NAC is not adequate to replace pathological assessment.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Proliferation and apoptosis before and after primary systemic therapy for operable breast cancer
    Guarneri, V.
    Piacentini, F.
    Frassoldati, A.
    Ficarra, G.
    Jovic, G.
    Puglisi, F.
    Michelotti, A.
    Bisagni, G.
    Berardi, R.
    Conte, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Diagnostic Accuracy of Axillary Ultrasound for Prediction of Axillary Pathologic Response after Neoadjuvant Treatment in Breast Cancer
    Tasdoven, Ilhan
    Erdemir, Rabiye Uslu
    Cakmak, Guldeniz Karadeniz
    CHIRURGIA, 2021, 116 (02) : S45 - S58
  • [33] Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer
    Chiba, Akiko
    Raman, Rachna
    Thomas, Alexandra
    Lamy, Pierre-Jean
    Viala, Marie
    Pouderoux, Stephane
    Mott, Sarah L.
    Schroeder, Mary C.
    Thezenas, Simon
    Jacot, William
    CLINICAL BREAST CANCER, 2018, 18 (02) : 144 - 149
  • [34] The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis
    Tang, Sudan
    Xiang, Chunhong
    Yang, Quan
    BRITISH JOURNAL OF RADIOLOGY, 2020, 93 (1112):
  • [35] Ultrafast Breast MRI to Predict Pathologic Response after Neoadjuvant Therapy
    Lee, Cindy S.
    Moy, Linda
    RADIOLOGY, 2022, 305 (03) : 575 - 577
  • [36] ADJUVANT SYSTEMIC THERAPY FOR OPERABLE BREAST-CANCER
    STEWART, HJ
    BRITISH MEDICAL BULLETIN, 1991, 47 (02) : 343 - 356
  • [37] PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST-CANCER
    ANDERSON, EDC
    FORREST, APM
    HAWKINS, RA
    ANDERSON, TJ
    LEONARD, RCF
    CHETTY, U
    BRITISH JOURNAL OF CANCER, 1991, 63 (04) : 561 - 566
  • [38] Primary and adjuvant systemic therapy for operable breast cancer
    Thomssen, C.
    Huober, J.
    ONKOLOGE, 2008, 14 (05): : 504 - 513
  • [39] Metaplastic Breast Cancer Has a Poor Response to Neoadjuvant Systemic Therapy
    Al-Hilli, Zahraa
    Jakub, James
    Visscher, Daniel
    Ingle, James
    Goetz, Matthew
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : 24 - 25
  • [40] The Accuracy of MRI in Predicting Pathologic Complete Response in Invasive Breast Cancer Patients Receiving Neoadjuvant Systemic Treatment.
    De Los Santos, J.
    Bernreuter, W.
    Keene, K.
    Krontiras, H.
    Carpenter, J.
    Bland, K.
    Cantor, A.
    Forero, A.
    CANCER RESEARCH, 2009, 69 (24) : 713S - 714S